logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Programmed Death Receptor-1 Blocking Antibody class drugs

    FiltersReset Filters
    8 results

    • jemperli

      (dostarlimab)
      GlaxoSmithKline LLC
      Usage: JEMPERLI is indicated for adults with primary advanced or recurrent endometrial cancer (EC) in combination with carboplatin and paclitaxel, followed by JEMPERLI alone. It also treats adults with mismatch repair deficient recurrent or advanced solid tumors that have progressed after prior treatment and lack satisfactory alternatives.

    • keytruda

      (pembrolizumab)
      Merck Sharp & Dohme LLC
      Usage: KEYTRUDA® is indicated for various cancers, including unresectable or metastatic melanoma; first-line treatments for non-small cell lung cancer, malignant pleural mesothelioma, head and neck squamous cell carcinoma; classical Hodgkin lymphoma; and many others. It targets PD-L1 expression and is applicable for both adult and pediatric patients.

    • loqtorzi

      (toripalimab-tpzi)
      Coherus BioSciences, Inc.
      Usage: LOQTORZI is indicated for the first-line treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma (NPC) in combination with cisplatin and gemcitabine. It is also indicated as a single agent for adults with recurrent unresectable or metastatic NPC progressing after platinum chemotherapy.

    • opdivo

      (nivolumab)
      E.R. Squibb & Sons, L.L.C.
      Usage: OPDIVO is indicated for the treatment of various cancers, including unresectable/metastatic melanoma, neoadjuvant and adjuvant non-small cell lung cancer, metastatic non-small cell lung cancer, malignant pleural mesothelioma, advanced renal cell carcinoma, classical Hodgkin lymphoma, and others. It is used in different combinations and settings based on the cancer type.

    • opdualag

      (nivolumab and relatlimab-rmbw)
      E.R. Squibb & Sons, L.L.C.
      Usage: OPDUALAG™ is indicated for the treatment of adult and pediatric patients aged 12 and older with unresectable or metastatic melanoma.

    • tecentriq

      (atezolizumab)
      Genentech, Inc.
      Usage: TECENTRIQ is indicated for treating various cancers, including: non-small cell lung cancer (adjuvant and metastatic), extensive-stage small cell lung cancer, unresectable or metastatic hepatocellular carcinoma, BRAF V600 mutation-positive melanoma, and unresectable or metastatic alveolar soft part sarcoma.

    • tecentriq hybreza

      (atezolizumab and hyaluronidase-tqjs)
      Genentech, Inc.
      Usage: TECENTRIQ HYBREZA is indicated for treating various cancers, including non-small cell lung cancer (NSCLC), small cell lung cancer (ES-SCLC), unresectable or metastatic hepatocellular carcinoma (HCC), BRAF V600 mutation-positive melanoma, and unresectable or metastatic alveolar soft part sarcoma (ASPS) in adults.

    • zynyz

      (retifanlimab-dlwr)
      Incyte Corporation
      Usage: ZYNYZ is indicated for treating adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). Its approval is based on tumor response and duration, with ongoing validation of clinical benefit required from confirmatory trials.